NASDAQ:CMPS - COMPASS Pathways Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $79.86
  • Forecasted Upside: 143.84 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$32.75
▲ +0.71 (2.22%)

This chart shows the closing price for CMPS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New COMPASS Pathways Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CMPS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CMPS

Analyst Price Target is $79.86
▲ +143.84% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for COMPASS Pathways in the last 3 months. The average price target is $79.86, with a high forecast of $120.00 and a low forecast of $50.00. The average price target represents a 143.84% upside from the last price of $32.75.

This chart shows the closing price for CMPS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 contributing investment analysts is to buy stock in COMPASS Pathways.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/22/2021HC WainwrightBoost Price TargetBuy$100.00 ➝ $120.00High
11/9/2021CitigroupBoost Price TargetBuy$66.00 ➝ $70.00High
11/9/2021Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$71.00 ➝ $82.00High
11/9/2021Roth CapitalBoost Price TargetBuy$79.00 ➝ $117.00High
10/28/2021OppenheimerInitiated CoverageOutperform$50.00High
7/13/2021CitigroupInitiated CoverageBuy$67.00Medium
7/1/2021HC WainwrightBoost Price TargetPositive$65.00 ➝ $100.00Medium
6/28/2021Berenberg BankReiterated RatingBuy$50.00Medium
6/28/2021Maxim GroupInitiated CoverageBuy$70.00High
5/11/2021Cantor FitzgeraldInitiated CoverageOverweight$71.00High
4/1/2021Roth CapitalInitiated CoverageBuy$88.00High
10/14/2020HC WainwrightInitiated CoverageBuy$65.00Low
10/13/2020Evercore ISIInitiated CoverageOutperformHigh
10/13/2020Canaccord GenuityInitiated CoverageBuy$80.00High
10/13/2020CowenInitiated CoverageOutperformHigh
10/13/2020Berenberg BankInitiated CoverageBuy$50.00High
(Data available from 11/27/2016 forward)

News Sentiment Rating

0.13 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 5 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
7/30/2021
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/29/2021
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
10/28/2021
  • 5 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 4 very negative mentions
11/27/2021

Current Sentiment

  • 5 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 4 very negative mentions

Recent Stories by Sentiment

COMPASS Pathways logo
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.
Read More

Today's Range

Now: $32.75
Low: $30.55
High: $32.75

50 Day Range

MA: $34.62
Low: $29.03
High: $48.96

52 Week Range

Now: $32.75
Low: $28.58
High: $61.69

Volume

359,614 shs

Average Volume

478,751 shs

Market Capitalization

$1.37 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.87

Frequently Asked Questions

What sell-side analysts currently cover shares of COMPASS Pathways?

The following Wall Street research analysts have issued research reports on COMPASS Pathways in the last twelve months: Berenberg Bank, Cantor Fitzgerald, Citigroup Inc., HC Wainwright, Maxim Group, Oppenheimer Holdings Inc., Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for CMPS.

What is the current price target for COMPASS Pathways?

7 Wall Street analysts have set twelve-month price targets for COMPASS Pathways in the last year. Their average twelve-month price target is $79.86, suggesting a possible upside of 143.8%. HC Wainwright has the highest price target set, predicting CMPS will reach $120.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $50.00 for COMPASS Pathways in the next year.
View the latest price targets for CMPS.

What is the current consensus analyst rating for COMPASS Pathways?

COMPASS Pathways currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CMPS will outperform the market and that investors should add to their positions of COMPASS Pathways.
View the latest ratings for CMPS.

How do I contact COMPASS Pathways' investor relations team?

The company's listed phone number is 1-646-905-3974 and its investor relations email address is [email protected] The official website for COMPASS Pathways is www.compasspathways.com.